POLE: Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer
Clinical and Applied Thrombosis/Hemostasis · 2026-01 · 32
DOI: 10.1177/10760296261428826 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Clinical and Applied Thrombosis/Hemostasis, online erschienen am 02.03.2026. Verfasst von Dongmei Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Pulmonary Embolism, Lung Neoplasms, Nomograms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Prediction models for cancer-associated pulmonary embolism (PE) in lung cancer patients are scarce. This study aimed to develop and validate a novel model to accurately predict PE risk in this population.
Methods
A retrospective cohort (n = 476) was used to identify PE-related risk factors and construct a predictive nomogram using Cox regression. Validation was performed in a prospective cohort (n = 140). The model's performance was compared with the Khorana score.
Results
The newly developed nomogram termed P ulmonary emb O lism in L ung canc E r ( POLE ) included seven variables: activated partial thromboplastin time, D-dimer, serum phosphorus, carbohydrate antigen 19-9, history of lung cancer surgery, targeted therapy, and age. It demonstrated good predictive performance in the retrospective study (area under the curve [AUC]: 0.776, 95% confidence interval [CI] 0.720-0.833, P < 0.001). The AUC values at 1, 3, 6, and 9 months after lung cancer diagnosis were 0.840, 0.839, 0.799, and 0.801, respectively. In the prospective study, the AUC values for the POLE model at 1, 3, 6, and 9 months after lung cancer diagnosis were 0.859, 0.806, 0.754, and 0.746, respectively. Moreover, in both derivation and validation cohorts, there were significant differences in the probability of PE occurrence among lung cancer patients being stratified into different risk strata (all P < 0.001). The POLE model (AUC 0.762) outperformed the Khorana score (AUC 0.560).
Conclusions
The POLE model, based on seven clinical parameters, was developed and validated for predicting cancer-associated PE in lung cancer patients, demonstrating high accuracy, calibration, and stability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Dongmei Wang, Wei Xiong, Xuan Huang, Fan Zhang, Fengming Xu, Fengfeng Han
Zitieren
APA
Wang, D., Xiong, W., Huang, X., Zhang, F., Xu, F., & Han, F. (2026). POLE: Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer. Clinical and Applied Thrombosis/Hemostasis, 32. https://doi.org/10.1177/10760296261428826
Vancouver
Wang D, Xiong W, Huang X, Zhang F, Xu F, Han F. POLE: Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer. Clinical and Applied Thrombosis/Hemostasis. 2026;32. doi:10.1177/10760296261428826
BibTeX
@article{Wang2026,
author = {Wang, Dongmei and Xiong, Wei and Huang, Xuan and Zhang, Fan and Xu, Fengming and Han, Fengfeng},
title = {POLE: Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer},
journal = {Clinical and Applied Thrombosis/Hemostasis},
year = {2026},
volume = {32},
doi = {10.1177/10760296261428826}
}
EUVIMED